Affinitak (ISIS 3521 or LY900003) : ISIS Pharmaceuticals : Antisense

Affinitak Phase III Trial Results in NCLC (ISIS Pharmaceuticals)
Press release announcing results of the Phase III trial comparing Affinitak plus carboplatin and paclitaxel to chemotherapy alone. There was no difference in overall survival between the two groups. Discusses additional findings. [3/03]